Clinical Research Directory
Browse clinical research sites, groups, and studies.
Gilteritinib in Combination With Venetoclax and Azacitidine for AML Patients With FLT3 Mutations Ineligible for Intensive Treatment
Sponsor: Technische Universität Dresden
Summary
Explore the best tolerable and efficacious dose of Gilteritinib when combined with standard treatment with Venetoclax and Azacitidine in AML patients with FLT3 mutations which are ineligible for intensive chemotherapy
Official title: Sequential Gilteritinib in Combination With Venetoclax and Azacitidine for Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) and FLT3 Mutations Ineligible for Intensive Treatment
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
60
Start Date
2025-04-25
Completion Date
2030-04
Last Updated
2025-05-29
Healthy Volunteers
No
Conditions
Interventions
Gilteritinib (GILT)
80 mg
Venetoclax (VEN)
400 mg
Azacitidine (AZA)
75 mg/m²
Locations (1)
Technische Universität Dresden
Dresden, Germany